- Home
- TGTX vs IEP Comparison
TGTX vs IEP Comparison
Compare TGTX & IEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- IEP
- Stock Information
- Founded
- TGTX 1993
- IEP 1987
- Country
- TGTX United States
- IEP United States
- Employees
- TGTX N/A
- IEP N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- IEP Auto Parts:O.E.M.
- Sector
- TGTX Health Care
- IEP Consumer Discretionary
- Exchange
- TGTX Nasdaq
- IEP Nasdaq
- Market Cap
- TGTX 5.4B
- IEP 6.0B
- IPO Year
- TGTX 1995
- IEP 1987
- Fundamental
- Price
- TGTX $32.91
- IEP $9.95
- Analyst Decision
- TGTX Strong Buy
- IEP
- Analyst Count
- TGTX 6
- IEP 0
- Target Price
- TGTX $40.67
- IEP N/A
- AVG Volume (30 Days)
- TGTX 2.3M
- IEP 1.0M
- Earning Date
- TGTX 11-04-2024
- IEP 11-08-2024
- Dividend Yield
- TGTX N/A
- IEP 35.51%
- EPS Growth
- TGTX N/A
- IEP N/A
- EPS
- TGTX N/A
- IEP N/A
- Revenue
- TGTX $264,790,000.00
- IEP $10,055,000,000.00
- Revenue This Year
- TGTX $43.74
- IEP N/A
- Revenue Next Year
- TGTX $64.30
- IEP N/A
- P/E Ratio
- TGTX N/A
- IEP N/A
- Revenue Growth
- TGTX 39.53
- IEP N/A
- 52 Week Low
- TGTX $12.84
- IEP $9.72
- 52 Week High
- TGTX $36.84
- IEP $22.59
- Technical
- Relative Strength Index (RSI)
- TGTX 55.20
- IEP 31.67
- Support Level
- TGTX $30.41
- IEP $9.77
- Resistance Level
- TGTX $35.03
- IEP $10.59
- Average True Range (ATR)
- TGTX 1.55
- IEP 0.30
- MACD
- TGTX -0.33
- IEP 0.01
- Stochastic Oscillator
- TGTX 51.78
- IEP 21.28
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
About IEP Icahn Enterprises L.P.
Icahn Enterprises LP is a provider of diversified business services in the United States. The company operates its business through varied segments which include Investment, Automotive, Energy, Food Packaging, Real Estate, Pharma, and Home Fashion. Among these, the Energy segment derives the maximum revenue from the company. Geographically, it generates maximum revenue from the United States.